Related Experiment Video
Updated: Feb 16, 2026

In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
An Industry Perspective on the 2017 EMA Guideline on First-in-Human and Early Clinical Trials
Joseph DeGeorge1, Sarah Robertson2, Lynne Butler3
1Bianca Holdings, Lansdale, Pennsylvania, USA.
Abstract:
The European Medicines Agency (EMA) in 2017 issued a revised guideline on nonclinical and clinical aspects of first-in-human (FIH) and early clinical trials (CTs). External input was solicited during a draft comment phase, and although some industry suggestions were adopted, others were not. We agree that subject safety is of utmost priority, and believe that minimizing risk must be balanced with efficient and informative study designs to bring new medicines to patients.
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Changes in Skin Color: Clinical Perspectives
Albinism
Albinism is a genetic disorder that affects (completely or partially) the coloring of skin, hair, and eyes. The defect is primarily...
Statistical Software for Data Analysis and Clinical Trials
Psychodynamic Perspectives on Personality
Psychodynamic theorists argue that unconscious...
Trial and Error and Algorithm

